{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:18:00Z","timestamp":1790983080479,"version":"4.1.0"},"reference-count":20,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hyperglycemia is an adverse effect of targeted cancer therapies; however, the mechanisms underlying B-Raf proto-oncogene, serine\/threonine kinase (BRAF)\/mitogen-activated protein kinase kinase (MEK) inhibitor-associated hyperglycemia remain unclear. We describe an 80-year-old man who developed severe hyperglycemia during combination therapy with dabrafenib and trametinib for BRAF V600E-positive lung adenocarcinoma. Before treatment, he was obese and had unrecognized mild diabetes. Seven months after treatment initiation, he presented with hyperglycemia accompanied by a reduced insulin secretory capacity. Serial measurements of the C-peptide index revealed that the temporary withdrawal of dabrafenib\u2013trametinib resulted in the recovery of insulin secretion, which gradually decreased again upon reinitiation. This case underscores the clinical importance of monitoring both the glycemic status and insulin secretion in patients receiving BRAF\/MEK inhibitors.<\/jats:p>","DOI":"10.1210\/jcemcr\/luag256","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:47:08Z","timestamp":1787226428000},"source":"Crossref","is-referenced-by-count":1,"title":["Dabrafenib and trametinib\u2013induced hyperglycemia with decreased insulin secretion in a patient with lung adenocarcinoma"],"prefix":"10.1210","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0555-1456","authenticated-orcid":false,"given":"Kohei","family":"Nagano","sequence":"first","affiliation":[{"name":"Department of Diabetes and Endocrine Disease, Kita-Harima Medical Center , Ono 675-1392 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0677-7828","authenticated-orcid":false,"given":"Masaki","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrine Disease, Kita-Harima Medical Center , Ono 675-1392 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saki","family":"Morikawa","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrine Disease, Kita-Harima Medical Center , Ono 675-1392 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikiya","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Kita-Harima Medical Center , Ono 675-1392 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Ohara","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrine Disease, Kita-Harima Medical Center , Ono 675-1392 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1987-9356","authenticated-orcid":false,"given":"Kenta","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrine Disease, Kita-Harima Medical Center , Ono 675-1392 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"issue":"Supplement_1","key":"2026090302545406500_luag256-B1","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.2337\/dc25-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142025","volume":"48","author":"ElSayed","year":"2025","journal-title":"Diabetes Care"},{"issue":"8","key":"2026090302545406500_luag256-B2","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/cam4.4579","article-title":"Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment","volume":"11","author":"Liu","year":"2022","journal-title":"Cancer Med"},{"issue":"1","key":"2026090302545406500_luag256-B3","doi-asserted-by":"crossref","first-page":"e142241","DOI":"10.1172\/JCI142241","article-title":"Insulin signaling in health and disease","volume":"131","author":"Saltiel","year":"2021","journal-title":"J Clin Invest"},{"issue":"5","key":"2026090302545406500_luag256-B4","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat Med"},{"issue":"6","key":"2026090302545406500_luag256-B5","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1634\/theoncologist.2017-0642","article-title":"FDA approval summary: dabrafenib and trametinib for the treatment of metastatic non-small cell lung cancers harboring BRAF V600E mutations","volume":"23","author":"Odogwu","year":"2018","journal-title":"Oncologist"},{"issue":"10","key":"2026090302545406500_luag256-B6","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial","volume":"18","author":"Planchard","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"2026090302545406500_luag256-B7","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/1758834014566428","article-title":"Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma","volume":"7","author":"Welsh","year":"2015","journal-title":"Ther Adv Med Oncol"},{"issue":"29","key":"2026090302545406500_luag256-B8","doi-asserted-by":"crossref","first-page":"21089","DOI":"10.1016\/S0021-9258(19)36801-2","article-title":"Sequential activation of MAP kinase activator, MAP kinases, and S6 peptide kinase in intact rat liver following insulin injection","volume":"267","author":"Tobe","year":"1992","journal-title":"J Biol Chem"},{"issue":"1-2","key":"2026090302545406500_luag256-B9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.mce.2013.05.021","article-title":"Hepatic ERK activity plays a role in energy metabolism","volume":"375","author":"Jiao","year":"2013","journal-title":"Mol Cell Endocrinol"},{"key":"2026090302545406500_luag256-B10","doi-asserted-by":"crossref","first-page":"1600251","DOI":"10.3389\/fphar.2025.1600251","article-title":"The role of ERK1\/2 signaling in diabetes: pathogenic and therapeutic implications","volume":"16","author":"Xu","year":"2025","journal-title":"Front Pharmacol"},{"issue":"6","key":"2026090302545406500_luag256-B11","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.coph.2009.07.004","article-title":"Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation","volume":"9","author":"Tanti","year":"2009","journal-title":"Curr Opin Pharmacol"},{"issue":"8","key":"2026090302545406500_luag256-B12","doi-asserted-by":"crossref","first-page":"E643","DOI":"10.1152\/ajpendo.00445.2015","article-title":"Targeting the ERK signaling pathway as a potential treatment for insulin resistance and type 2 diabetes","volume":"310","author":"Ozaki","year":"2016","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"7","key":"2026090302545406500_luag256-B13","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.2337\/db20-1295","article-title":"MEK\/ERK signaling in \u03b2-cells bifunctionally regulates \u03b2-cell mass and glucose-stimulated insulin secretion response to maintain glucose homeostasis","volume":"70","author":"Ikushima","year":"2021","journal-title":"Diabetes"},{"issue":"35","key":"2026090302545406500_luag256-B14","doi-asserted-by":"crossref","first-page":"32969","DOI":"10.1074\/jbc.M301198200","article-title":"Regulation of insulin gene transcription by ERK1 and ERK2 in pancreatic beta cells","volume":"278","author":"Khoo","year":"2003","journal-title":"J Biol Chem"},{"issue":"1","key":"2026090302545406500_luag256-B15","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2337\/db12-0454","article-title":"A genome-wide association study identifies GRK5 and RASGRP1 as type 2 diabetes loci in Chinese Hans","volume":"62","author":"Li","year":"2013","journal-title":"Diabetes"},{"issue":"10","key":"2026090302545406500_luag256-B16","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/ng.3943","article-title":"Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with coronary heart disease","volume":"49","author":"Zhao","year":"2017","journal-title":"Nat Genet"},{"key":"2026090302545406500_luag256-B17","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.molmet.2019.03.004","article-title":"Laser capture microdissection of human pancreatic islets reveals novel eQTLs associated with type 2 diabetes","volume":"24","author":"Khamis","year":"2019","journal-title":"Mol Metab"},{"issue":"7534","key":"2026090302545406500_luag256-B18","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nature13887","article-title":"An ERK\/Cdk5 axis controls the diabetogenic actions of PPAR\u03b3","volume":"517","author":"Banks","year":"2015","journal-title":"Nature"},{"issue":"4","key":"2026090302545406500_luag256-B19","first-page":"183","article-title":"A case of diabetes mellitus that developed during combination therapy of dabrafenib-trametinib for lung adenocarcinoma","volume":"65","author":"Suda","year":"2022","journal-title":"J Japan Diab Soc"},{"issue":"9626","key":"2026090302545406500_luag256-B20","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/S0140-6736(08)60762-X","article-title":"Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial","volume":"371","author":"Weng","year":"2008","journal-title":"Lancet"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/9\/luag256\/70935043\/luag256.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/9\/luag256\/70935043\/luag256.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:55:03Z","timestamp":1788418503000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luag256\/8780890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,7,27]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luag256","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,7,27]]},"article-number":"luag256"}}